Home > Haematology > ASH 2021 > Acute Myeloid Leukaemia > Comparable effectiveness of CPX-351 and venetoclax plus HMA in older AML patients

Comparable effectiveness of CPX-351 and venetoclax plus HMA in older AML patients

Presented By
Dr Justin Grenet, Weill Cornell Medical Center, NY, USA
Conference
ASH 2021
Liposomal daunorubicin/cytarabine (CPX-351) therapy did not result in different overall survival (OS) outcomes or response rates than venetoclax plus hypomethylating agent (HMA) therapy in patients with acute myeloid leukaemia (AML) between 60 and 75 years of age in this retrospective, real-world study. Subgroup analyses displayed an advantage in OS for TP53-positive patients who were treated with CPX-351 [1]. Both CPX-351 and venetoclax plus an HMA combination therapy have demonstrated to improve OS in older patients with AML [2,3]. Dr Justin Grenet (Weill Cornell Medical Center, NY, USA) and colleagues conducted a real-world, multicentre, retrospective chart review to compare the effectiveness of CPX-351 (n=211) versus venetoclax plus HMA (n=226). Primary outcomes were response rate, OS, and relapse-free survival. Dr Grenet explained that CPX-351 therapy is usually prescribed to younger patients who are deemed f...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on